Charnwood Discovery’s Post

How many of you include clinically-relevant biomarkers in early drug discovery? In this blog you can learn how that could positively affect the clinical outcomes using ALS as an example of the current landscape. Share your thoughts in the comments #ALS #drugdiscovery #biomarkers

Are you aware of the recent failures of ALS drugs in clinical trials? In this blog we provide insights on the recent setbacks, discuss the increasing need for reliable biomarkers and a path forward with iPSC technology. Read the article here: https://lnkd.in/dTZYBDpv Key highlights: - These recent failures underscore a persistent issue in ALS research: the gap between preclinical success and clinical efficacy - Incorporating relevant biomarkers, like NfL, into the evaluation process can enhance the predictive power of preclinical models - iPSC technology enables studying the disease in a human context, with key biomarkers, providing more accurate predictions on disease mechanisms and drug responses. #news #ALS #stemcell #drugdiscovery #biomarkers #iPSCtechnology

🤔Lost in the maze of #AntibodyProduction methods? Let us simplify your decision-making! With endless project deadlines and complex experimental setups, finding the best antibody production method can be daunting for any researcher. Should you go with hybridoma, phage display, or polyclonal production? ✅ Don’t waste precious time! In just 10 questions and less than 2 minutes, our interactive quiz will guide you to the ideal solution tailored to your project’s needs. Whether you are working on therapeutics, diagnostics, or research, ProteoGenix’s expertise ensures precise and reliable answers to optimize your workflow. 👉 Try the quiz now and let us help you drive your project forward with confidence: https://lnkd.in/ewXtq6Cg #Hybridoma #PhageDisplay #PolyclonalAntibodies

Biomarkers Market | Growing at CAGR 10.2% 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 👉https://lnkd.in/eg8rG-Gp The size of global biomarkers market in terms of revenue was estimated to be worth $57.7 billion in 2024 and is poised to reach $93.8 billion by 2029, growing at a CAGR of 10.2% from 2024 to 2029. Companies From the Market BioAgilytix Bill & Melinda Gates Medical Research Institute Owkin Scipher Medicine  Quanterix Metabolon, Inc.      Kura Oncology, Inc. InsideTracker Advanced Cell Diagnostics  Biodesix, Inc. Eurofins Central Laboratory    Biocare Medical   Koneksa Clinical ink BrainScope Ikena Oncology QMENTA Feel Therapeutics KCAS Bio Denali Therapeutics #Biomarkers #Healthcare #Research #Medicine #Innovation #Science #Biotechnology #PrecisionMedicine #Diagnostics #BiomarkerDiscovery #HealthTech #MedicalResearch #PersonalizedMedicine #BiomarkerTesting #ClinicalTrials #Bioinformatics #HealthScience #BiomarkerDevelopment #PrecisionHealth #MedicalInnovation

GRI Bio, Inc. announced positive preclinical results for their lead program, GRI-0621, targeting Idiopathic Pulmonary Fibrosis (IPF). GRI-0621 is an iNKT cell inhibitor that has shown significant reductions in fibrosis and inflammation in preclinical models. Phase 2a biomarker study data is expected in Q3 2024, with topline results anticipated in Q4 2024. IPF is a challenging condition with limited treatment options, and GRI Bio’s advancements could lead to major improvements in patient outcomes. If you are passionate about contributing to groundbreaking biotech advancements, let's connect. I can help you explore opportunities where your expertise can drive forward innovative treatments. #BiotechCareers #IPF #ClinicalResearch

Clinical trials on metastatic hormone-sensitive and castration-resistant #ProstateCancer have shown improved benefits from various drugs. While ongoing research aims to clarify sequencing, treatment de-escalation, and biomarkers, the real challenge lies in translating this evidence into everyday clinical practice 🔬 Read the latest insights on these pivotal developments from Deborah Mukherji plus much more ➡️ https://lnkd.in/eqC4DT_D

Glioblastoma is the most complex, treatment-resistant and deadliest type of brain cancer. Ongoing research is needed to find new and better ways to tackle this devastating cancer. Learn 👇 how #Abcam helps you speeding up your #glioblastomaresearch. #ProgressHappensTogether #glioblastoma #braintumors #cancerresearch

Small airway epithelial cells are the unsung heroes of our respiratory system 🌟 These cells play a vital role in maintaining lung function, barrier integrity, and mucociliary clearance. Similarly, the interaction between the different cell types is fundamental to be able to predict the effect that drugs may have on their function. Derived from primary cells, our SAEC model comprises all key epithelial cell types: basal, club (Clara), goblet, and ciliated cells. 🔬Our human Small Airway Epithelial Cell (SAEC) Model could provide your next step to developing better lung therapeutics. Applications and Impact of our SAEC Model: 1. Toxicity assessment 2. Efficacy and target engagement screening Discover how our SAEC model could transform your research: https://lnkd.in/eEeJKjbX #NewcellsBiotech #Lung #BiotechInnovation

How critical is your time? For innovators racing to be first-to-publish or first-to-market, every second counts. Yet, common obstacles like high reagent costs, long turnaround times, and complex data analysis can slow progress. Our new digital Handbook shows how High-Throughput Screening (HTS) by Cytometry transforms cell analysis workflows, delivering the speed, throughput, and simplicity that traditional systems can't match.  Find in-depth information, validated assays, and example data about the application you care about. Topics covered: ✅ Cell Health ✅ Secreted Proteins ✅ Cell Line Development ✅ Biologics Discovery ✅ Immune Cell Models  ✅ Cell Therapy   Access now: https://ow.ly/P4oY50TvTzI #antibodies #lifesciences #HighThroughputScreening #Cytometry #HTS #immunecellprofiling #celllinedevelopment #antibodydiscovery #celltherapy #immunooncology #advancedcellmodels #cellhealth #apoptosis #cytotoxicity #inducedpluripotentstemcells #iPSCs

🔬 🧫 🧬 Don’t miss out on an exclusive roundtable discussion on "Developing Therapies that Target Multiple Immune Pathways" at the Antibody Therapeutics Xchange - Brussels! 🗓 18 Nov 2024 | 09:05 - 10:05 CET 📍 Bi/Multispecifics Track Key topics include: ✅ Optimal design for a multispecific TCE - what have we learned, and what’s next? ✅ Improving tumor selectivity - do we need new combinations of TAAs? ✅ Checkpoint inhibition - address it in the same molecule or separately? 🔑 Led by Leonard Wossnig, CTO at LabGenius an expert in AI, quantum machine learning, and computational drug design. 💡 Secure your FREE spot! https://lnkd.in/eQWzNrAH Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AntibodyTherapeutics #BiSpecifics #Multispecifics #CancerResearch #Immunotherapy #AIInHealthcare #LabGenius #DrugDiscovery #PrecisionMedicine #ImmunePathways #TCellEngagers #CheckpointInhibition #Oncology #Pharma #Biotech #HealthcareInnovation #Xchange2024 #PharmaTech #Biopharma #Brussels2024 #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass